Wet Macular Degeneration
Showing 1 - 25 of 3,798
Age-related Wet Macular Degeneration Trial in United States (CG-P5 peptide, Placebo, Aflibercept Injection [Eylea])
Not yet recruiting
- Age-related Wet Macular Degeneration
- CG-P5 peptide
- +2 more
-
Augusta, Georgia
- +3 more
Nov 13, 2023
Neovascular Age-related Macular Degeneration Trial (RRG001)
Not yet recruiting
- Neovascular Age-related Macular Degeneration
- (no location specified)
Nov 15, 2023
Single Injection of Faricimab for nAMD With Persisting Fluid
Active, not recruiting
- Neovascular Age-related Macular Degeneration
-
Glostrup, DenmarkMiklos Schneider
Nov 3, 2023
Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD) Trial (aflibercept 8 mg PFS)
Not yet recruiting
- Diabetic Macular Edema (DME)
- Neovascular Age-Related Macular Degeneration (nAMD)
- aflibercept 8 mg PFS
- (no location specified)
Aug 3, 2023
Artificial Intelligence Diagnostic Aid
Not yet recruiting
- Wet Macular Degeneration
- +2 more
- Macusense Assessment Software
-
London, Westminster, United KingdomGuy's and St Thomas's NHS Foundation Trust
Dec 29, 2022
Neovascular Age-related Macular Degeneration Trial in Graz (Aflibercept 40 MG/ML, Faricimab 120 MG/ML)
Recruiting
- Neovascular Age-related Macular Degeneration
- Aflibercept 40 MG/ML
- Faricimab 120 MG/ML
-
Graz, Styria, AustriaDepartment of Ophthalmolgy, Medical University Graz
Jul 3, 2023
Neovascular Age-related Macular Degeneration Trial in Suzhou (Aflibercept Ophthalmic, IBI302)
Not yet recruiting
- Neovascular Age-related Macular Degeneration
- Aflibercept Ophthalmic
- IBI302
-
Suzhou, Jiangsu, ChinaInnovent Biologics (Suzhou) Co,Ltd.
Jul 25, 2023
Neovascular Age-related Macular Degeneration Trial in Phoenix (CLS-AX, Aflibercept)
Recruiting
- Neovascular Age-related Macular Degeneration
-
Phoenix, ArizonaRetinal Research Institute, LLC
Jun 4, 2023
Neovascular Age-related Macular Degeneration Trial (PMC-403)
Not yet recruiting
- Neovascular Age-related Macular Degeneration
- (no location specified)
Jul 11, 2023
Neovascular Age-related Macular Degeneration Trial (AXT107 Low Dose, AXT107 Mid Dose, AXT107 High Dose)
Not yet recruiting
- Neovascular Age-related Macular Degeneration
- AXT107 Low Dose
- +2 more
- (no location specified)
May 5, 2023
Neovascular Age-related Macular Degeneration (nAMD) Trial in Abilene (OCU-10-C-110 for Injection)
Not yet recruiting
- Neovascular Age-related Macular Degeneration (nAMD)
- OCU-10-C-110 for Injection
-
Abilene, TexasRetina Research Institute of Texas
Jun 6, 2023
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema Trial in Beijing (Intravitreal injection of IBI302(dose 1),
Suspended
- Neovascular Age-related Macular Degeneration
- Diabetic Macular Edema
- Intravitreal injection of IBI302(dose 1)
- +3 more
-
Beijing, Beijing, ChinaPeking University People's Hospital
Jul 17, 2023
Neovascular Age-related Macular Degeneration Trial (FT-003)
Not yet recruiting
- Neovascular Age-related Macular Degeneration
- FT-003
- (no location specified)
Nov 21, 2022
Russian Registry of Patients With nAMD
Terminated
- Neovascular Age-Related Macular Degeneration
- nAMD
- (no location specified)
Jan 16, 2023
Neovascular Age-related Macular Degeneration(nAMD) Trial in Shanghai, Tianjin (HG202)
Not yet recruiting
- Neovascular Age-related Macular Degeneration(nAMD)
- HG202
-
Shanghai, Shanghai, China
- +1 more
Sep 4, 2023
Neovascular Age-related Macular Degeneration Trial in Katy, Norfolk (SKG0106)
Not yet recruiting
- Neovascular Age-related Macular Degeneration
- SKG0106
-
Katy, Texas
- +1 more
Aug 15, 2023
Neovascular Age-related Macular Degeneration Trial in Shanghai (LX102-C01 Injection)
Active, not recruiting
- Neovascular Age-related Macular Degeneration
- LX102-C01 Injection
-
Shanghai, ChinaShanghai General Hospital, Shanghai Jiao Tong University School
Apr 14, 2023
Age-Related Macular Degeneration Trial in Toronto (NG101 AAV gene therapy)
Not yet recruiting
- Age-Related Macular Degeneration
- NG101 AAV gene therapy
-
Toronto, Ontario, CanadaVitreous Retina Macula Specialists of Toronto
Aug 2, 2023
Neovascular Age-related Macular Degeneration (nAMD) Trial (AR-14034 SR implant lower dose, Aflibercept Injection, Sham
Not yet recruiting
- Neovascular Age-related Macular Degeneration (nAMD)
- AR-14034 SR implant lower dose
- +3 more
- (no location specified)
Mar 3, 2023
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema Trial in Austin (AIV007)
Not yet recruiting
- Neovascular Age-related Macular Degeneration
- Diabetic Macular Edema
-
Austin, TexasRetina Consultants of Austin
Jan 16, 2023
Neovascular Age-related Macular Degeneration Trial in Beijing (IBI333)
Not yet recruiting
- Neovascular Age-related Macular Degeneration
- IBI333
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital, Chinese Academy of Medica
Nov 28, 2022
Learn More About How Well Aflibercept 8 mg Works in Treating
Not yet recruiting
- Visual Impairment
- +2 more
- Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
-
Multiple Locations, Australia
- +5 more
Oct 4, 2023
Macular Degeneration, Wet, Metamorphopsia Trial
Recruiting
- Macular Degeneration, Wet
- Metamorphopsia
-
Cuneo, Piedmont, ItalyOspedale Santa Croce
Sep 20, 2022
Neovascular Age-related Macular Degeneration (NVAMD), Diabetic Macular Edema (DME) Trial in United States (EYE103)
Recruiting
- Neovascular Age-related Macular Degeneration (NVAMD)
- Diabetic Macular Edema (DME)
-
Phoenix, Arizona
- +4 more
Jun 14, 2023
Exudative Age Related Macular Degeneration Trial in Winston-Salem (Ranibizumab, Photodynamic laser treatment (PDT),
Not yet recruiting
- Exudative Age Related Macular Degeneration
- Ranibizumab
- +3 more
-
Winston-Salem, North CarolinaWake Forest Health Sciences
Nov 28, 2022